Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.

Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, Littlewood TD, Evan GI.

Cell. 2017 Nov 30;171(6):1301-1315.e14. doi: 10.1016/j.cell.2017.11.013.

2.

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.

NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.

3.

An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer.

Olow A, Chen Z, Niedner RH, Wolf DM, Yau C, Pankov A, Lee EP, Brown-Swigart L, van 't Veer LJ, Coppé JP.

Cancer Res. 2016 Apr 1;76(7):1733-45. doi: 10.1158/0008-5472.CAN-15-2325-T. Epub 2016 Feb 26.

4.

Validation of MdmX as a therapeutic target for reactivating p53 in tumors.

Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegué E, Evan GI.

Genes Dev. 2011 Aug 15;25(16):1746-57. doi: 10.1101/gad.16722111.

5.

Selective activation of p53-mediated tumour suppression in high-grade tumours.

Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP.

Nature. 2010 Nov 25;468(7323):567-71. doi: 10.1038/nature09526.

6.

Distinct thresholds govern Myc's biological output in vivo.

Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI.

Cancer Cell. 2008 Dec 9;14(6):447-57. doi: 10.1016/j.ccr.2008.10.018.

7.

Modeling the therapeutic efficacy of p53 restoration in tumors.

Martins CP, Brown-Swigart L, Evan GI.

Cell. 2006 Dec 29;127(7):1323-34. Epub 2006 Dec 21.

8.

The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta.

Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI.

Genes Dev. 2006 Sep 15;20(18):2527-38.

9.

Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.

Lawlor ER, Soucek L, Brown-Swigart L, Shchors K, Bialucha CU, Evan GI.

Cancer Res. 2006 May 1;66(9):4591-601.

10.

Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo.

Dansen TB, Whitfield J, Rostker F, Brown-Swigart L, Evan GI.

J Biol Chem. 2006 Apr 21;281(16):10890-5. Epub 2006 Feb 7.

11.

Temporal dissection of p53 function in vitro and in vivo.

Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW, Evan GI.

Nat Genet. 2005 Jul;37(7):718-26. Epub 2005 May 29.

Supplemental Content

Loading ...
Support Center